Bevacizumab抑制骨溶解的实验研究

目的：观察局部注射不同浓度的血管内皮生长因子抑制剂bevacizumab对磨损颗粒诱导骨溶解的抑制作用。方法：建立磨损颗粒诱导骨溶解的植骨气囊动物模型,分别在bevacizumab低剂量组（C组）和bevacizumab高剂量组（D组）小鼠气囊内隔天注入0.2 mL 25μg·mL^-1和250μg·mL^-1 Bevacizumab溶液,空白对照组（A组）和阳性对照组（B组）则以等量生理盐水取代,2周后观察囊壁炎症反应及骨溶解情况。结果：阳性对照组囊壁红肿及血管增生明显重于空白对照组,不同剂量bevacizumab组（C、D组）囊壁红肿及血管增生轻于阳性对照组。HE染色显示不同剂量bevacizumab组囊壁厚度、细胞密度均明显低于阳性对照组（P〈0.05）,并随浓度增加而降低（P〈0.05）,骨片边缘骨破坏也轻于阳性对照组。实时荧光定量PCR及ELISA显示不同剂量bevacizumab组炎性因子表达明显低于阳性对照组（P〈0.05）。结论：局部注射Bevacizumab可抑制磨损颗粒诱导的炎症反应及骨溶解。

Bevacizumab inhibits wear particle-induced osteolysis in a mouse model

Objective： To observe the effect of local injection of different concentrations of VEGF inhibitor bevacizumab on the wear particle-induced osteolysis. Motheds： An mouse Bone implant in air pouch model for wear particle-induced osteolysis were established. 0. 2 mL bevacizumzb were injected into the air pouches in low-dose bevacizumzb group（ 25 μg·mL^- 1） and high-dose Bevacizumab group（ 250 μg·mL^- 1）,In blank control group and positive control group,saline was used. 2 weeks later,observe the inflammatory reaction and bone resorption of the pouch membranes. Results： The redness,swelling,and neovascularization in air pouches of positive control group were more obvious than blank control group and the two different concentrations of bevacizumzb group were slighter than positive control group. Hematoxylin-eosin staining indicated that the thickness and the cell density of the pouch membrane in two different concentrations of bevacizumab group were significantly lower than those in positive control group. As bevacizumab concentration increased,the index decreased accordingly. Real-time fluorescent quantitative PCR and ELISA analyses showed that The expression of inflammatory cytokines in two different concentrations of bevacizumzb group were Far lower than positive control group. Conclusion： Local injection of bevacizumab can effectively inhibit wear particle-induced inflammatory responses and osteolysis.